Navigation Links
Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75

ts (pts) with metastatic androgen-independent prostate cancer (AIPC) -- Y. Ning, MD; Abstract #5114; June 3, 2007; 2:00-6:00pm; McCormick Place Convention Center, S Hall A2

Data Presented Monday, June 4

Oral Presentation: Melphalan-Prednisone-Thalidomide (MP-T) is also superior to Melphalan-Prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo-controlled IFM 01-01 trial -- C. Hulin, IFM, France; Abstract #8001; June 4, 2007; 7:30-7:45am; McCormick Place Convention Center, E Arie Crown Theater

Factors predictive of outcome in relapsed, refractory MM patients treated with bortezomib, melphalan, prednisone and thalidomide (VMPT) -- A. Palumbo; Abstract #8048; June 4, 2007; 2:00-6:00pm; McCormick Place Convention Center, E451a

A systematic review of the incidence of venous thromboembolism (VTE) and effectiveness of prophylaxis in patients with multiple myeloma (MM) receiving thalidomide -- C. Wu, M.D.; Abstract #9056; June 4, 2007; 2:00-6:00pm; McCormick Place Convention Center, S Hall A2

A Phase II trial of thalidomide (Thal) and procarbazine (Pro) in adults with recurrent or progressive malignant gliomas (MG) -- G. Lesser, MD; Abstract #2067; June 4, 2007; 1:00-5:00pm; McCormick Place Convention Center, S Hall A2

About Thalidomide Pharmion

Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma after the failure of standard therapies.

In markets where Thalidomide Pharmion is not approved, such as the E.U., Thalidomide Pharmion is currently provided on a named patient/compassionate use basis and under an Autorisation Temporaire d'Utilisation (ATU) in France while the Company seeks an approval. Pharmion is the only provider of thalidomide outside of the US with a comprehensive safety program in place. The Company holds exclusive marketin
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
3. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
4. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
5. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
6. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
9. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
10. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
11. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
Post Your Comments:
(Date:1/6/2009)... In recent controlled studies condu...s , scientists found that the patented ingredient ...nly proven ingredient to increase levels of nitric...nitrate/nitrate (NOx) in human subjects. , , Ni...crease in blood flow to the skeletal muscles. Thi...
(Date:1/6/2009)...uary 6 , - Early ...on Until,December 2011 , - Expansion of th...Discovery in Ophthalmology , - Revised Comm...Sublicenses to a Third Party , ExonHit Th...inforcement,of its existing drug discovery collab...
(Date:12/30/2008)...RNewswire-USNewswire/ -- The Coalition for 21st Ce...on filed by Genentech, Inc. on December 5, 2008, s...offer diagnostic tests to physicians and patients....ests, would harm patient care and rests on flawed ...n,s mission is to encourage the research, developm...
(Date:12/17/2008)...in development and validation of non-animal altern... 17 MatTek Corporation today annou...(ESAC) endorsed the scientific validity of the Mod...vember meeting. ESAC concluded that the Modified ...y for the prediction of skin irritating and non-ir...
Breaking Medicine Technology:US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4EpiDerm's Skin Irritation Test Fully Validated in European Union 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 1Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 3Pharsight Expands Global Consulting Services Teams 3640 1Pharsight Expands Global Consulting Services Teams 3640 2Pharsight Expands Global Consulting Services Teams 3640 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 1Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 4Study 3A Modafinil is effective in treating excessive sleepiness 3637 1Study 3A Modafinil is effective in treating excessive sleepiness 3637 2
...swire-FirstCall/ -- Vical,Incorporated today annou...e company,s Vaxfectin(TM) adjuvant elicited protec... (1 - 2 year old),nonhuman primates confirmed by c...ne year after vaccination, and sterilizing,immunit... no,detectable virus after challenge. In a separat...
...007 /PRNewswire-FirstCall/ -- Alexza,Pharmaceutica...he,49th Annual American Headache Society Meeting t...to(R) prochlorperazine (AZ-001),for the acute trea...n, "Efficacy and tolerability profile of AZ-001,(S...e headache",(Poster S-72), will be available for v...
Other Medicine Technology:Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 2Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 3Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 4Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at,the American Headache Society Meeting 2
(Date:1/8/2009)...swire/ -- A study released this week showing that ...ultiple chronic diseases shines a much-needed spot...stem to one that focuses on primary and secondary ... the leader in disease prevention. , , (Logo:...TU129LOGO ) , , The study, conducted by Socia...
(Date:1/8/2009)...ember Tom Torlakson Introduces AB 89 , , SACRAM...Today, Lung Cancer Alliance-California (LCA-CA), h...11th District) for his continued leadership in int...ncer research. For the third consecutive year, le...being considered in the California Legislature. ...
(Date:1/8/2009)...emn hurtful comments, study suggests , ,... overestimate how strongly they would react to rac...hree percent of study participants at York Univers...eriment with a white person rather than a black on...s about the black person when he left the room. ,...
(Date:1/8/2009)...8 Hanger Orthopedic Grou... throughout the fourth quarter of 2008 it acquired...y Mountain Orthotic-Prosthetics Center, Riessen,s ...ast Orthotics & Prosthetics, and Orthopedic Re... patient care centers to existing markets in Maine...
Breaking Medicine News(10 mins):Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Many Turn Blind Eye to Racism 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2
...ique Federale de Lausanne) and the CHUV (Lausanne ...ls in the hair follicle belong to the true multipo...nto many cell types needed for hair growth and fol...has documented its findings in an advance online p...
...ue of the journal Pediatrics says that the cavity ... of Cow's milk. Dr. Ruth A. Lawrence of the Unive...e Dr. William H. Bowen used rats to demonstrate th...se tooth decay faster than cow's milk. Baby mice d...
...of Multiple Sclerosis (MS), has been withdrawn fro...mplained of neurological disorders. The relationsh...Leukoencephalopathy (PML) is being researched by t...gnificant risk, it could be a serious setback for ...
...g a glassful of dangerous bacteria, not many will ...however did just that. He swallowed a cocktail of ...rial in origin rather than stress or lifestyle-rel... proved very useful as his colleague Robin Warren ...
Other Medicine News:Health News:Nobel For Ulcer-Defying Aussie Scientists 2
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: